-
- Comment in:
-
Adv Anat Pathol. 2005 Mar;12(2):47-52.
-
Science. 2004 Jun 4;304(5676):1458-61.
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
Paez JG,
Jänne PA,
Lee JC,
Tracy S,
Greulich H,
Gabriel S,
Herman P,
Kaye FJ,
Lindeman N,
Boggon TJ,
Naoki K,
Sasaki H,
Fujii Y,
Eck MJ,
Sellers WR,
Johnson BE,
Meyerson M.
Departments of Medical Oncology and Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue. Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15of 58 unselected tumors from Japan and 1 of 61 from the United States. Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan. EGFR mutations were found in additional lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines. These results suggest that EGFR mutations may predict sensitivity to gefitinib.
PMID: 15118125 [PubMed - indexed for MEDLINE]
-
Cited by over 100 PubMed Central articles
-
EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer.
Gerber DE.
Drug Dev Res. 2008 Dec 9; 69(6):359-372.
[Drug Dev Res. 2008]
-
Epidermal growth factor receptor mutations and the clinical outcome in male smokers with squamous cell carcinoma of lung.
Park SH, Ha SY, Lee JI, Lee H, Sim H, Kim YS, Hong J, Park J, Cho EK, Shin DB, et al.
J Korean Med Sci. 2009 Jun; 24(3):448-52. Epub 2009 Jun 12.
[J Korean Med Sci. 2009]
-
Can systems biology understand pathway activation? Gene expression signatures as surrogate markers for understanding the complexity of pathway activation.
Itadani H, Mizuarai S, Kotani H.
Curr Genomics. 2008 Aug; 9(5):349-60.
[Curr Genomics. 2008]
- » See all...